GenomeWeb - OpGen

Channel: GenomeWeb - OpGen

↧

OpGen Files for $6.5M Public Offering of Common Stock

:0

:0

March 4, 2019, 8:52 am

View Article

OpGen Prices $5.4M Public Offering

:0

:0

March 26, 2019, 7:17 am

View Article

OpGen Submits Antibiotic Resistance Test to FDA

:0

:0

May 14, 2019, 6:49 am

View Article

OpGen Posts 18 Percent Rise in Q1 Revenues

:0

:0

May 15, 2019, 5:44 am

View Article

OpGen Q2 Revenues Climb 28 Percent

:0

:0

August 8, 2019, 7:16 am

View Article

OpGen Progresses on Pipeline of Highly Multiplexed Drug-Resistant Bacteria Tests

:0

:0

August 20, 2019, 10:44 am

View Article

OpGen Stock Non-Compliant With Nasdaq Listing Requirement

:0

:0

August 23, 2019, 1:53 pm

View Article

OpGen Plans Reverse Stock Split

:0

:0

August 28, 2019, 10:50 am

View Article

OpGen, Curetis Enter Merger Agreement

:0

:0

September 4, 2019, 7:50 am

View Article

Curetis Reports 36 Percent Increase in H1 Revenues

:0

:0

September 18, 2019, 7:05 am

View Article

OpGen Plans $10.4M Stock, Warrant Sale

:0

:0

October 15, 2019, 10:13 am

View Article

OpGen Prices $9.4M Stock, Warrant Offering

:0

:0

October 24, 2019, 7:08 am

View Article

OpGen Posts 17 Percent Increase in Q3 Revenues

:0

:0

November 6, 2019, 2:09 pm

View Article

Curetis Posts 17 Percent Increase in Preliminary Revenues for First Nine...

:0

:0

November 14, 2019, 6:38 am

View Article

Curetis Reports 17 Percent Revenue Increase for First Nine Months of 2019

:0

:0

November 25, 2019, 7:19 am

View Article

FDA Clears Curetis Lower Respiratory Tract Infections Panel

:0

:0

December 20, 2019, 4:38 pm

View Article

Ares Genetics Collaborates With BGI on Coronavirus Testing in Europe

:0

:0

January 30, 2020, 7:58 am

View Article

OpGen Preliminary 2019 Revenues up 19 Percent

:0

:0

February 12, 2020, 7:44 am

View Article

Curetis Preliminary 2019 Revenues Up 64 Percent

:0

:0

February 20, 2020, 7:41 am

View Article

OpGen Fourth Quarter Revenues Increase 8 Percent

:0

:0

March 24, 2020, 4:24 pm

View Article

© 2025 //www.rssing.com